NNVC ▼ -0.8% - NanoViricides, Inc. $NNVC - NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives 05-OCT-2026 08:45 AM ET